Skip to content
OpenCapital
Get started

Lexicon Pharmaceuticals LXRX Accrued financing costs

Other financials

Income statement

See full
Revenue$21.1M+1,572%
Gross profit$21.0M+1,604%
Operating income-$996.0K+96.1%
Net income-$1.0M+95.9%
EPS (diluted)$0.00+100%

Balance sheet

See full
Cash & equivalents$67.1M+6.7%
Total debt$57.7M-45.7%
Total equity$202.9M+64.9%
Total assets$268.8M-9.7%

Cash flow

See full
Operating cash flow-$14.7M+66.4%
CapEx--100%
Free cash flow-$17.2M+21.5%

Valuation

See full
Market cap$986.12M+273%
Enterprise value$976.73M+219%
P/S14.2×+5.7×

Profitability

See full
Gross margin99.5%+1.5pp
Operating margin-34.8%-16.8pp
Net margin-37.5%-18.1pp
FCF margin-578.5%-283pp

Returns & leverage

See full
Return on equity-16%-7.2pp
Debt / equity0.3×-0.6×
Current ratio18.8×+16.6×

Where this comes from

Reported directly by Lexicon Pharmaceuticals in its filing.

Tagged under the XBRL concept lxrx:FinancingCostsAccrued.

The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lexicon Pharmaceuticals's accrued financing costs.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Lexicon Pharmaceuticals's accrued financing costs?
Lexicon Pharmaceuticals (LXRX) reported accrued financing costs of $313K in Q1 2026.